Cite

    Jürgen Harreiter et al.. “Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24‐week, prospective, randomized, placebo‐controlled pilot trial.” Diabetes, obesity & metabolism, vol. 23, no. 5, 2021, pp. 1129–1139. http://access.bl.uk/ark:/81055/vdc_100127528868.0x00001b